Kahweol Inhibits Pro-Inflammatory Cytokines and Chemokines in Tumor Necrosis Factor- α/Interferon-γ-Stimulated Human Keratinocyte HaCaT Cells
Curr Issues Mol Biol. 2024 Apr 18;46(4):3470-3483. doi: 10.3390/cimb46040218.ABSTRACTAtopic dermatitis (AD), marked by intense itching and eczema-like lesions, is a globally increasing chronic skin inflammation. Kahweol, a diterpene that naturally occurs in coffee beans, boasts anti-inflammatory, antioxidative, and anti-cancer properties. This research explores the anti-inflammatory action of kahweol on HaCaT human keratinocytes stimulated by tumor necrosis factor-α (TNF-α) and interferon-γ (IFN-γ), focusing on key signal transduction pathways. Our results demonstrate that kahweol markedly reduces the production of IL-...
Source: Current Issues in Molecular Biology - April 26, 2024 Category: Molecular Biology Authors: Ye Jin Kwon Hyun Hee Kwon Jaechan Leem Yoon Young Jang Source Type: research
Eczema Coxsackium: Atypical Manifestations in the Comorbidity of Atopic Dermatitis With Hand, Foot, and Mouth Disease Caused by Coxsackievirus A6 in a Pediatric Case
Dermatitis. 2024 Apr 25. doi: 10.1089/derm.2024.0031. Online ahead of print.NO ABSTRACTPMID:38662460 | DOI:10.1089/derm.2024.0031 (Source: Dermatitis)
Source: Dermatitis - April 25, 2024 Category: Dermatology Authors: Mutong Zhao Xu Li Lin Ma Source Type: research
Molecules, Vol. 29, Pages 1972: Pharmacological Activities of Lonicerae japonicae flos and Its Derivative & mdash; & ldquo;Chrysoeriol & rdquo; in Skin Diseases
Conclusion: The cutaneous route is the best delivery approach to chrysoeriol across the skin barrier. However, toxicity, dosage, and safety assessments of chrysoeriol in a formulation or nanochrysoeriol on the human epidermis for application in skin diseases must be further investigated. (Source: Molecules)
Source: Molecules - April 25, 2024 Category: Chemistry Authors: Siu Kan Law Xiao Xiao Wu Zhou Jiang Christy Wing Sum Tong Wesley Yeuk Lung Chow Dawn Ching Tung Au Tags: Review Source Type: research
Effectiveness of atopic dermatitis patient education programs – a systematic review and meta-analysis
In this study, we conducted a systematic review of the literature to determine the effectiveness of online programming in AD education compared to in-person interventions. A comprehensive search was conducted in accordance with the Cochrane Handbook for Systematic Reviews of Interventions 2019. Studies were retrieved based on articles published up to 04 April 2023. Adherence to the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) Statement guided the reportage process for this systematic review and meta-analysis. The primary outcome of our meta-analysis was the effect of various educational modali...
Source: Archives of Dermatological Research - April 25, 2024 Category: Dermatology Source Type: research
Immunologic Profiling of Immune-Related Cutaneous Adverse Events with Checkpoint Inhibitors Reveals Polarized Actionable Pathways
CONCLUSIONS: Distinct immunologic ircAE endotypes suggest actionable targets for precision medicine-based interventions.PMID:38652814 | DOI:10.1158/1078-0432.CCR-23-3431 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - April 23, 2024 Category: Cancer & Oncology Authors: Mario E Lacouture Elena Goleva Neil Shah Veronica Rotemberg Lukas Kraehenbuehl Kwami F Ketosugbo Taha Merghoub Tara Maier Alexander Bang Stephanie Gu Trina Salvador Andrea P Moy Taras Lyubchenko Olivia Xiao Clifton F Hall Evgeny Berdyshev James Crooks Rya Source Type: research
Immunologic Profiling of Immune-Related Cutaneous Adverse Events with Checkpoint Inhibitors Reveals Polarized Actionable Pathways
CONCLUSIONS: Distinct immunologic ircAE endotypes suggest actionable targets for precision medicine-based interventions.PMID:38652814 | DOI:10.1158/1078-0432.CCR-23-3431 (Source: Cancer Control)
Source: Cancer Control - April 23, 2024 Category: Cancer & Oncology Authors: Mario E Lacouture Elena Goleva Neil Shah Veronica Rotemberg Lukas Kraehenbuehl Kwami F Ketosugbo Taha Merghoub Tara Maier Alexander Bang Stephanie Gu Trina Salvador Andrea P Moy Taras Lyubchenko Olivia Xiao Clifton F Hall Evgeny Berdyshev James Crooks Rya Source Type: research
Long-term effectiveness and safety of upadacitinib for Japanese patients with moderate-to-severe atopic dermatitis: a real-world clinical study
CONCLUSIONS: Upadacitinib was therapeutically effective and tolerable for moderate-to-severe AD through 48 weeks in real-world clinical practice.PMID:38653561 | DOI:10.1080/09546634.2024.2344591 (Source: Herpes)
Source: Herpes - April 23, 2024 Category: Infectious Diseases Authors: Teppei Hagino Hidehisa Saeki Eita Fujimoto Naoko Kanda Source Type: research
Long-term effectiveness and safety of upadacitinib for Japanese patients with moderate-to-severe atopic dermatitis: a real-world clinical study
CONCLUSIONS: Upadacitinib was therapeutically effective and tolerable for moderate-to-severe AD through 48 weeks in real-world clinical practice.PMID:38653561 | DOI:10.1080/09546634.2024.2344591 (Source: Journal of Dermatological Treatment)
Source: Journal of Dermatological Treatment - April 23, 2024 Category: Dermatology Authors: Teppei Hagino Hidehisa Saeki Eita Fujimoto Naoko Kanda Source Type: research
Immunologic Profiling of Immune-Related Cutaneous Adverse Events with Checkpoint Inhibitors Reveals Polarized Actionable Pathways
CONCLUSIONS: Distinct immunologic ircAE endotypes suggest actionable targets for precision medicine-based interventions.PMID:38652814 | DOI:10.1158/1078-0432.CCR-23-3431 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - April 23, 2024 Category: Cancer & Oncology Authors: Mario E Lacouture Elena Goleva Neil Shah Veronica Rotemberg Lukas Kraehenbuehl Kwami F Ketosugbo Taha Merghoub Tara Maier Alexander Bang Stephanie Gu Trina Salvador Andrea P Moy Taras Lyubchenko Olivia Xiao Clifton F Hall Evgeny Berdyshev James Crooks Rya Source Type: research
[[Translated article]]Dupilumab to Treat Chronic Palmoplantar Eczema: A Retrospective Multicenter Cohort Study
Actas Dermosifiliogr. 2024 Apr 21:S0001-7310(24)00350-8. doi: 10.1016/j.ad.2024.04.010. Online ahead of print.NO ABSTRACTPMID:38653369 | DOI:10.1016/j.ad.2024.04.010 (Source: Actas Dermo-Sifiliograficas)
Source: Actas Dermo-Sifiliograficas - April 23, 2024 Category: Dermatology Authors: J Magdaleno-Tapial A Torrijos Aguilar V Gonz ález-Delgado P Hern ández-Bel Source Type: research
Long-term effectiveness and safety of upadacitinib for Japanese patients with moderate-to-severe atopic dermatitis: a real-world clinical study
CONCLUSIONS: Upadacitinib was therapeutically effective and tolerable for moderate-to-severe AD through 48 weeks in real-world clinical practice.PMID:38653561 | DOI:10.1080/09546634.2024.2344591 (Source: Herpes)
Source: Herpes - April 23, 2024 Category: Infectious Diseases Authors: Teppei Hagino Hidehisa Saeki Eita Fujimoto Naoko Kanda Source Type: research
Long-term effectiveness and safety of upadacitinib for Japanese patients with moderate-to-severe atopic dermatitis: a real-world clinical study
CONCLUSIONS: Upadacitinib was therapeutically effective and tolerable for moderate-to-severe AD through 48 weeks in real-world clinical practice.PMID:38653561 | DOI:10.1080/09546634.2024.2344591 (Source: Journal of Dermatological Treatment)
Source: Journal of Dermatological Treatment - April 23, 2024 Category: Dermatology Authors: Teppei Hagino Hidehisa Saeki Eita Fujimoto Naoko Kanda Source Type: research
[[Translated article]]Dupilumab to Treat Chronic Palmoplantar Eczema: A Retrospective Multicenter Cohort Study
Actas Dermosifiliogr. 2024 Apr 21:S0001-7310(24)00350-8. doi: 10.1016/j.ad.2024.04.010. Online ahead of print.NO ABSTRACTPMID:38653369 | DOI:10.1016/j.ad.2024.04.010 (Source: Actas Dermo-Sifiliograficas)
Source: Actas Dermo-Sifiliograficas - April 23, 2024 Category: Dermatology Authors: J Magdaleno-Tapial A Torrijos Aguilar V Gonz ález-Delgado P Hern ández-Bel Source Type: research
Long-term effectiveness and safety of upadacitinib for Japanese patients with moderate-to-severe atopic dermatitis: a real-world clinical study
CONCLUSIONS: Upadacitinib was therapeutically effective and tolerable for moderate-to-severe AD through 48 weeks in real-world clinical practice.PMID:38653561 | DOI:10.1080/09546634.2024.2344591 (Source: Journal of Dermatological Treatment)
Source: Journal of Dermatological Treatment - April 23, 2024 Category: Dermatology Authors: Teppei Hagino Hidehisa Saeki Eita Fujimoto Naoko Kanda Source Type: research
